Similarly, after ANKL patient’s hyperinflammatory condition was alleviated (or cooled) by HLH-2004-like chemotherapy, PD-1 antibodies could be integrated into the ensuing intensified chemotherapy (consolidation), such as the GLIDE regimen, which was designed for NK/T cell lymphoma by our colleagues Ji J et al (26). Here, PDCD1 is linked to T-cell non-Hodgkin lymphoma.